Bozeman, MT-based LigoCyte Pharmaceuticals has rounded up $28 million in its third round of venture capital. The money will be used for the clinical development of two lead vaccines targeting norovirus and influenza. Forward Ventures, JAFCO, and Novartis Venture Fund led the round with Fidelity Biosciences and MedImmune Ventures participating. Report